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ATCC25923 - WT WT 6.25 0.75 0.75
ATCC25923EtBr - WT WT 200 25 12.5
SM1 A2 S80Y/E84G S84L 16 4 4
SM10 A4 S80Y/E84G S84L 16 2 4
SM14 A3 S80Y/E84G S84L 16 4 4
SM17 A4 S80Y/E84G S84L 16 4 4
SM25 A1 S80Y/E84G S84L 8 2 4
SM27 A4 S80Y/E84G S84L 16 4 4
SM43 A1 S80Y/E84G S84L 16 2 4
SM46 A1 S80Y/E84G S84L 16 4 4
SM47 A1 S80Y/E84G S84L 8 2 4
SM48 A1 S80Y/E84G S84L 8 4 4
SM50 B1 S80F/E84K S84L 8 1 2
SM52 C1 S80Y S84L 16 1 2
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reproduction in any medium, provided the orS80Y/E84G; isolate SM52 carries the GrlA mutation
S80Y; isolates SM3 and SM5 carry the GrlA double mu-
tation S80F/E84G. The correct data can be found in
Table 1.
All clinical isolates included in this study were selected
upon a ciprofloxacin resistance phenotype and all the 25
representative isolates screened for mutations conferringus clinical isolates
MIC (mg/L)c
CIP NOR NAL
No + + No + + No + +
EI TZ CPZ EI TZ CPZ EI TZ CPZ
0.25 0.125 0.125 0.5 0.125 0.125 64 n.d. n.d.
1 0.25 0.25 2 0.25 0.25 64 n.d. n.d.
128 32 64 512 128 256 256 64 64
128 64 64 512 128 128 128 64 64
256 32 128 1024 128 256 256 64 64
256 64 64 1024 256 512 256 64 64
128 32 64 512 64 128 256 32 64
256 32 64 512 128 256 256 64 64
128 64 64 512 128 128 512 256 64
128 64 64 512 128 256 128 64 64
256 32 64 512 128 256 256 64 64
256 32 64 512 128 256 256 64 64
64 16 16 256 32 64 128 64 64
16 8 8 64 32 32 128 32 64
td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Genotypic and phenotypic characterization of S. aureus clinical isolates (Continued)
SM2 B2 S80F/E84K S84L 8 2 2 32 16 16 128 32 32 64 16 64
SM3 E1 S80F/E84G S84L 1 1 1 16 8 8 64 32 32 64 16 16
SM4 E2 S80F S84L 4 2 1 8 8 8 64 32 32 64 32 64
SM5 E3 S80F/E84G S84L 4 2 1 32 16 16 128 64 64 64 32 32
SM6 A5 S80F E88K 4 2 1 16 16 16 64 32 32 64 32 32
SM7 E1 S80F S84L 2 2 1 8 8 4 64 32 32 128 32 64
SM8 A5 S80F E88K 4 2 1 16 8 16 128 64 64 128 32 64
SM12 E1 S80F S84L 2 2 1 16 8 8 64 32 32 128 32 64
SM16 A6 S80F E88K 4 2 1 16 16 16 128 32 64 64 32 64
SM22 A1 S80Y/E84G S84L 8 4 4 128 16 32 512 128 128 64 32 64
SM34 D1 S80F/E84K S84L 4 2 2 64 16 32 64 16 32 32 16 32
SM36 E1 S80F S84L 4 2 2 16 8 8 64 16 32 128 32 64
SM40 E1 S80F S84L 8 4 4 32 32 32 512 128 128 16 8 16
aIsolates in bold correspond to the EtBrCW-positive isolates. bWT: wild-type; S: serine; F: phenylalanine; E: glutamate; K: lysine; Y: tyrosine; L: leucine; G: glycine.
cValues in bold-type correspond to a MIC decrease of ≥ four-fold in the presence of the efflux inhibitor (EI) in comparison to the values with no EI [10]. The
concentration of each EI used is defined in the Methods section. EtBr: ethidium bromide; CIP: ciprofloxacin; NOR: norfloxacin; NAL: nalidixic acid; TZ: thioridazine;
CPZ: chlorpromazine; n.d.: not determined.
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both grlA and gyrA genes. All the mutations found have
been described in literature as associated with fluoro-
quinolone resistance in S. aureus clinical isolates [2]. As
stated previously in our study, the majority of the iso-
lates presented a double mutation in GrlA together with
a single mutation in GyrA. Eleven isolates carried the
GrlA and GyrA mutations S80Y/E84G and S84L, re-
spectively; three isolates carried mutations GrlA S80F/
E84K and GyrA S84L and two isolates carried mutations
GrlA S80F/E84G and GyrA S84L.The remaining nine
isolates carried a single mutation in both genes, in three
distinct arrangements (Table 1).
Despite this correction in the QRDR mutations carried
by some of the isolates studied, the main findings of our
study are not altered. In particular, our data show the
potential role played by efflux systems in the develop-
ment of resistance to fluoroquinolones in clinical isolates
of S. aureus, independently of the mutations occurring
in the target genes.
We apologize for any inconvenience that this may
have caused to the readers.
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